Lupin sees opportunity to launch around 30 generic products in the world's largest pharmaceuticals market this year.
Biocon said it has received EIR from the US health regulator on closure of inspection of its sterile drug product manufacturing facility in Bengaluru.
Cipla said it has received final nod from the US health regulator for generic Testosterone Cypionate injection used for replacement therapy in males for deficiency.
Drug major Cipla today said it has received approval from the US health regulator to market Efavirenz tablets, used to treat HIV-1 infections in adults.
Glenmark Pharmaceuticals said the US health regulator has approved the first product from its Monroe, North Carolina based manufacturing facility.
Drug firm Zydus Cadila today said it has received approval from the US health regulator to market Tadalafil tablets, used to erectile dysfunction, in the American market.
Drug firm Strides Shasun today said it has received approval from the US health regulator to market Ketoconazole tablets, used to treat fungal infections, in the American market.
Dr Reddy's Laboratories said that a US District Court has issued a temporary restraining order on the sale and commercialisation of its generic Buprenorphine and Naloxone sublingual film in US.
At NSE, shares of the company went up by 4.80 per cent to Rs 2,378.50.
Shares of Alembic Pharmaceuticals today rose by over 3 per cent after the company received approval from the US health regulator for its Doxycycline Hyclate capsules.
Mulls 1:1 Bonus Share Issue
CITY UNION BANK
To Issue 1:10 Bonus Shares; Record Date At July 11
Approved Bonus Issue Of 1:2; Record Date At June 27
Arm Buys Under-Construction Asset For Rs 234 Cr In Indore At Auction
Brownfield Acquisition To Add Approx. 1.1 Mn Sq. Ft. To Co's Retail Portfolio
Co In Pact To Buy 95% Of Climate Tech Pty, Australia
Deal Size Stands At Rs 201-211 Cr In Valuation
JLR Investor Presentation:
Have Exciting Products, Plans In The Pipeline To Generate Sustainable Growth
Aiming For A 4-7% EBIT Margin Over Medium Term, Will Invest 4.5 Bn GBP In FY19-21
Aiming For A 7-9% EBIT Margin Over Long Term
Long Term Investment Pegged At 12-13% Of Revenue
Retail Volume Grew By 1.7% & Revenue Grew By 6% In FY18
Also Launched Jaguar I-Pace As Co's First All Battery Electric Vehicle
To Set Up 5 Lk KL/Annum Plant At Visakhapatnam For Rs 1,785 Cr
To Set Up 6 Lk KL/Annum Plant In Mysore For Rs 2,300 Cr
Co's International Business Did Not Perform Well In FY18
Economy & Inflated Currency Hit Co's Egyptian Operations
To Launch Generic Tadalafil After Filing ANDA With USFDA
Sterile Drug Product Manufacturing Facility In Bengaluru Receives EIR From USFDA
USFDA's Pre-Approval & Inspection Of Facility Done In April & May 2018
EIR Notifies That The Inspection Stands Closed
Co Committed To Global Standards Of Quality & Compliance
Dr Reddy's Loses Patent Case With Eli Lilly Over Alimta
Co Cannot Launch Its Alternative Salt Forms Until The Eli Lilly Patent Expires
The U.S. District Court For The Southern District Of Indiana Ruled In Favour Of Lilly
The Eli Lilly Patent Expires In May 2022